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Abstract
Background: Intraductal papillary mucinous neoplasms (IPMNs) are increasingly recognized entities, whose
management remains sometimes controversial, due to the high rate of benign lesions and on the other side to
the good survival after resection of malignant ones.
Methods: Retrospective analysis of a prospectively collected Western series of IPMN.
Results: Forty cases of IPMN were analysed (1992-2007). Most patients were symptomatic (72.5%); cholangio-MRI
had the best diagnostic accuracy both for the tumour nature (83.3%) and for the presence of malignancy (57.1%).
ERCP was done in 8 cases (20%), and the results were poor. Thirteen patients were treated by pancreatic resection
and 27 were maintained in follow-up. Total pancreatectomy was performed in 46% of the cases; in situ and
invasive carcinoma were recognized in 15.4% and 38.4% of the cases, respectively. The mean follow-up was
42 months (range 12-72). One only patients with nodal metastases died 16 months after the operation for disease
progression, while 91.6% of the operated patients are disease free. Out of the 27 not resected patients, 2 out of
4 presenting a lesion at high risk for malignancy died, while the remaining are in good conditions and disease
free, with a mean follow-up of 31 months.
Conclusion: Therapeutic indication for IPMNs is mainly based upon radiological evaluation of the risk of
malignancy. While the main duct tumours should be resected, preserving whenever possible a portion of the
gland, the secondary ducts tumours may be maintained under observation, in absence of radiological elements of
suspicion such as size larger than 3 cm, or a wall greater than 3 mm or nodules or papillae in the context of the
cyst.
Background
In the group of cystic neoplasms of the pancreas, the
intraductal papillary mucinous tumor (IPMN) represents
a recently characterized entity; this denomination was
introduced in 1996 [1], and comprises a group of lesions
that differ from cystic mucinous neoplasms because of a
direct communication with the Wirsung duct and the
absence of ovarian-type stroma [2]; it is characterized by
a papillary growth of the ductal epithelium with rich
mucin production and cystic expansion of the interested
duct (Fig. 1).
IPMN was firstly described in 1982 [3]; a sharp
increase in the frequency of such observations in the
following years sets the doubt of a possible new environ-
mental stimulus or a genetic mutation: the hypothesis
that before 1980 the IMPNs were simply otherwise clas-
sified clashes with the lack of findings of similar
tumours in some retrospective revisions [4]. Natural his-
tory of this tumour is different from ductal adenocarci-
noma: in 90-100% of the cases it is resectable, with
survival reaching 80-90% for in situ carcinoma, 50-70%
for invasive carcinoma and 40-50% when nodal meta-
stases are already present [5]. Some preoperative indica-
tors of malignancy were proposed, and their accuracy is
actually under prospective evaluation [2].
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In this paper we present the series of cystic intraductal
tumours observed by the Surgical Clinic of the Brescia
University, with the aim to underline the clinical pro-
blems they set, related both to the therapeutic indication
and to the extension of surgical demolition, and to com-
pare the results with those previously reported in
Literature.
Methods
All cases with a definite diagnosis of IPMN (i.e., a cystic
neoplasm with a demonstrated communication with or
a direct involvement of the Wirsung duct) were taken
into consideration. In the period 1992 to 2007, 276
patients affected by pancreas neoplasm have been sub-
mitted to surgical exploration, and 186 have been
resected, 13 of them with a definitive pathological diag-
nosis of intraductal papillary mucinous tumor; starting
from 2004, on the basis of the literature indications, the
cases of IPMN of the secondary ducts of small size have
been maintained in follow-up (23 patients); further 4
cases of IPMN suspected for malignancy were not sub-
mitted to surgery for an elevated surgical risk (advanced
age, cardio-respiratory and liver morbidity); so, the pre-
sent paper analyzes in total 40 patients with IPMN, 13
treated by surgery and 27 submitted to follow-up.
We considered and recorded as possible risk factors
for malignancy smoke, alcoholism, carcinogens expo-
sure, diabetes mellitus, biliary lithiasis, chronic pancrea-
titis, neoplasms of other organs [5]. CEA and CA 19.9
were recorded in all the patients. Imaging has been
analyzed to verify the diagnostic accuracy both for the
diagnosis of nature and for the diagnosis of malignancy.
In the group of patients submitted to invasive investiga-
tions (ERCP with brushing and/or biopsy-aspiration of
the cystic content) we considered indications, complica-
tions and the influence of the results upon the final
therapeutic decision. At the conclusion of the diagnostic
workup, IPMNs were subdivided into main duct
tumours (MDTs) and branch duct tumours (BDTs). In
accordance with the Literature, an high risk for malig-
nancy was hypothesized for all MDT and for BDT larger
than 3 cm, or with a wall greater than 3 mm or with
nodules of papillae in the context of the cyst [2]. For
diagnostic considerations, those criteria were employed
also for the cases observed before the publication of the
International Consensus Guidelines in 2006; previous
cases were retrospectively re-evaluated.
In patients submitted to surgical intervention, the
extension of the resection has always been driven by the
preoperative evaluation of the dilated Wirsung duct and
by the intraoperative histological examination of the
pancreatic cut surface in partial pancreatectomy: in case
of presence of IPMN in the cut surface, even if without
dysplasia, we extended the resection until a completely
negative cut section. In the final histopathological exam-
ination the WHO classification was followed [6], divi-
ding the cases into 4 groups: IPMAdenoma (dysplasia of
low degree), IPMN border-line (dysplasia of moderate
degree), in situ IPMCarcinoma and infiltrating IPMCar-
cinoma. For the 27 patients not submitted to pancreatic
resection, the distinction of benign from malignant
lesions has been based on the evolution at follow-up, as
already proposed [2].
The mean follow-up was 42 months (range 12-72),
47 months (range 15-72) for the operated patients and
31 months (range 12-51) for the observed ones. The fol-
low-up protocol for the operated patients foresees controls
at 3, 6, 12, 18, 24 months and subsequently every
12 months up to 5 years. Such controls included clinical
examination, tumour markers, abdominal ultrasound or
CT or cholangio-MRI, according to the clinical suspicion
(in absence of any suspect of recurrence, CT every year for
patients with carcinoma and cholangio-MRI every year for
patients with benign neoplasm were performed). In the
not resected patients, instead, the follow-up was almost
entirely founded on the cholangio-MRI, to reduce expo-
sure of the patient to radiations.
Results
The relative incidence of the IPMNs in the pancreatic sur-
gical series of the Brescia University Surgical Clinic clearly
increased from the period 1992-2003 to 2004-2007: 3/122
(2.4%) versus 10/64 resections (15.6%). The 40 patients
affected by IPMN were 21 women and 19 males (Table 1).
Figure 1 Main duct IPMN, a Wirsung section shows the
epithelial proliferation covered by papillae with abundant
mucus production.
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The majority of them were symptomatic (29/40, 72.5%);
such percentage was slightly different in resected (61.5%)
and not resected patients (77.7%), p = 0.19. The most fre-
quent symptoms were acute pancreatitis (18 cases, 62% of
the symptoms and 45% of all the patients with IPMN) and
abdominal pain (4 cases, 13.7% of the symptoms). In 11
cases (27.5%) the IPMN was incidentally discovered during
ultrasonographic investigation performed for follow-up of
other neoplasms (5 cases) or for different reasons
(6 cases). An increase of CA 19.9 was documented in
3 patients, while CEA always resulted normal.
Table 2 reports data related to the diagnostic course.
In most cases the first examination setting the suspicion
of IPMN has been the ultrasound (24 cases, 60%), after
which CT or MRI were done in all the patients, the
diagnostic accuracy of cholangio-MRI being clearly
superior (83%), given its ability to show the communica-
tion of the cyst with the Wirsung duct. Despite the
above examinations substantially brought elements ade-
quate to set the diagnosis of IPMN in 37/40 patients, in
many cases the radiologist required a diagnostic confir-
mation by ERCP. Nevertheless, ERCP was done only in
8 patients (20%), and the results were poor, because a
correct spatial definition of the Wirsung duct involve-
ment was obtained only in 4 cases (50%), and the pan-
creatic brushing was possible only in 5 cases (62.5%),
with negative results in all but one (resulting doubtful);
in 50% of the cases ERCP was followed by pancreatitis
that lasted for various weeks, making it necessary to
delay surgical intervention in 2 patients and making
more difficult the pancreatic resection in one. In 3 cases
we proceeded to aspiration of the cystic content by
echo-endoscopy for biochemical and cytological exami-
nation, always with negative result. In 7 cases a PET
scan was also performed, with 2 positive and 5 negative
results [7].
At the completion of the pre-operative study, on the
basis of the previously reported criteria [2], malignancy
could be suspected in 17/40 patients (42.5%) from the
morphological characteristics (14 cases), brushing cytol-
ogy (1 case), CA 19.9 rise (3 cases) and indicative symp-
toms as jaundice and weight loss (2 cases). Thirteen out
of these 17 patients were operated on and 4 were not,
because of high surgical risk. Performed interventions
are reported in Table 3. In 2 cases the positive intra-
operative frozen section examination of the margin
imposed to extend the resection up to a total pancrea-
tectomy. A lymphadenectomy was associated to the pan-
creatic resection in 7 patients, removing the nodes
anterior and posterior to the pancreas head, those of
celiac artery, hepatic artery, common bile duct and
those of the root of the superior mesenteric vein. It was
never necessary to associate vascular and visceral
resections.
In all the resected cases the conclusive diagnosis has
been IPMN. Ten cases have been classified as main duct
tumour (MDT) and 3 as branch duct tumour (BDT).
This corresponded to the preoperative classification
based on the imaging in all the cases. Location and size
are reported in Table 3. If we consider benign the ade-
noma IPMNs and the border-line IPMNs, and malig-
nant those with carcinoma in situ or infiltrating,
7 resected lesions were malignant (53,8%). Based upon
the reported morphological criteria [2], and the final
assessment of the radiologist, when clearly expressed,
the preoperative diagnostic accuracy in differentiating
benign from malignant IPMN was 69.2% (9/13 patients).
On the basis of the definitive histological examination,
in all the patients the resection has been considered R0.
In no case a positive margin was found at the final
pathology. One only patient had metastatic nodes.
We complain the death at 62th post-operative day of
the patient, already described, submitted to total pan-
createctomy for a main duct IPMN, after having
Table 1 Clinical characteristics of 40 patients with
intraductal papillary mucinous neoplasm (IPMN)
n. pts. %
Patients
Middle age (range) 68.3 years (36-83)
Male (mean age) 21 (73 years)
Female (mean age) 19 (65.9)
Presence of risk factors
Biliary lithiasis 7 17.5
Other tumours 5 12.5
Symptomatic at diagnosis 29 72.5
Acute Pancreatitis 18 45.0
Abdominal pain 4 10.0
Diabetes 1 2.5
Diarrhea 1 2.5
Jaundice 1 2.5
Anorexia 1 2.5
Tumor markers
Raised Ca 19.9 3 7.5
Raised CEA 0
Table 2 Diagnostic accuracy of imaging techniques
employed in 40 patients with IPMN
ultrasound
(26 pts.)
CT
(31 pts.)
MR
(24 pts.)
n % n % n %
Correct diagnosis of IPMN 4 15.4 11 35.4 20 83.3
Correct diagnosis of malignancy° 1/3 33.3 2/4 50.0 4/7 57.1
Correct diagnosis of extension§ 1 25.0 9/11 81.8 22 100
° Reference parameter was final histological diagnosis of malignant IPMN
§Reference parameter was macroscopic pathology for resected patients and
MRI for the others
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experienced acute pancreatitis post ERCP and with a
post-operative course complicated by delayed gastric
emptying and respiratory sepsis. The overall morbidity
of the series (30.7%) includes 2 low-flow fistulas, conser-
vatively treated, a gastrojejunostomy hemorrhage, endos-
copically treated, and a pulmonary embolism. Among
minor complications, 3 pleural effusions, 1 wound infec-
tion and 2 troubles of the glycemic control were
recorded. Eleven out of the 12 patients who survived
after the resection are alive and disease-free. The patient
presenting nodal metastases had a relapse after 12
months and deceased 16 months after the operation.
Out of the 27 not resected patients, 2 out of 4 present-
ing a lesion at high risk for malignancy died, the first 6
months after the diagnosis for disease progression, the
second at 16 months for decompensation of a pre-exist-
ing Child C liver cirrhosis. The remaining 25 patients,
including the 2 remaining whose lesions presented
aspects indicative of potential malignancy, are in good
conditions and disease free, with a mean follow-up of 31
months.
Discussion
Malignant IPMN represents a good surgical indication,
as Literature survival data report [8-11], and our series
confirms. Nevertheless, controversies remain, relative to
the diagnostic protocol to be adopted, to the surgical
indication in the IPMNs at low risk of malignancy, and
finally to the extension of pancreatic resection.
The first problem is the identification of the tumour.
IPMNs are symptomatic in most cases, with acute pan-
creatitis due to duct obstruction from mucus or from the
papillary proliferations. In the present series, less than
half of the patients had an episode of acute pancreatitis;
among these, only 27.7% had a history of biliary stones
and 5.5% of alcoholism. Only in 1 case imaging demon-
strated a severe pancreatitis. Thus, the typical presenta-
tion has been a recurrent acute pancreatitis, without
evident cause, of low or moderate severity, but with a
log-standing asymptomatic hyperlipasemia. Such set of
symptoms must lead to suspect the existence of an intra-
ductal cause, that can be confirmed by further diagnostic
steps, such as cholangio-MRI. The remaining half of the
patients with IPMN are asymptomatic, and the tumour is
discovered incidentally, often during abdominal ultra-
sound performed for other reasons [12]. Also in these
cases the colangio-MRI has elective indication to demon-
strate the intraductal nature of the lesion, eventually
communicating with the Wirsung duct.
Cholangio-MRI is confirmed from our data to be
superior to CT scan in the study of IPMN patients
(Table 2). It doesn’t emerge from our experience any sub-
stantial advantage from ERCP. The only potential added
value of such an invasive procedure, the Wirsung duct
brushing, finds heavy limits in its extremely low sensibil-
ity. In our experience, in half cases the contrast medium
wasn’t able to depict the whole cystic or polycystic lesion
shown by cholangio-MRI, because of the density of its
mucous content. Furthermore, ERCP may harbour in
these patients an increased risk of complications (e. g.
acute pancreatitis), which can heavily interfere with the
eventual surgical option. Fifty per cent of the IPMN
patients submitted to ERCP developed a iatrogenic pan-
creatitis in our experience, percentage much higher than
ERCP for other diseases. One of these patients had a
postoperative course dramatically complicated, con-
cluded by death in 62th day. Surprisingly, this idea was
not previously underlined in the Literature. There is no
evidence that further invasive diagnostic procedures,
such as wirsungscopy, echo-endoscopy with biopsy or
fine needle sample and percutaneous biopsy, may war-
rant a substantial improvement in diagnostic accuracy
[13,14]. Starting from 2006, we planned a prospective
study on the use of 18-FDG-PET to differentiate benign
from malignant lesions [7]. Such technique is able to
Table 3 Surgical and pathological characteristics of 13
patients with resected intraductal papillary mucinous
neoplasm (IPMN)
N. %
Therapy
Resection 13 32.5
Mean age (range) 68.8 (57-81)
Total Pancreatectomy 6 46.1
Left Pancreatectomy 5 38.4
Duodeno-pancreatectomy 2 15.4
Lymphadenectomy 7* 53.8
Pathology
MDT 10 76.9
BDT 3 23.1
Location
Head 3 23.1
Body-Tail 5 38.4
Whole Wirsung 5 38.4
WHO classification
Adenoma 4 30.7
Borderline 2 15.4
In situ carcinoma 2 15.4
Infiltrating carcinoma 5 38.4
Middle diameter (range) 3.92 cm (1.8-6 cm)
Nodal metastases 1/7 14.3
Postoperative
Mortality 1 7.7
Morbidity 4 30.7
*112 nodes were retrieved in total (mean 16/patient)
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demonstrate some increased metabolic signal in nodules
or solid papillae lying in the context of the cystic wall
[15]. The results gathered from our first 28 patients
demonstrated an improvement in specificity compared to
cholangio-MRI alone (specificity 43% with the MRI,
100% with MRI plus PET), nevertheless such data are in
progress and they are not extensively introduced in this
paper.
So, the diagnosis of IPMN is usually based upon the
imaging (CT/cholangio-MRI) demonstrating a pancrea-
tic cystic mass, involving a dilated main duct, eventually
associated to some filling defects (MDT, principal duct),
or a normal Wirsung duct communicating with the cyst
lesion (BDT, secondary ducts).
Many papers analysed the predictive factors for malig-
nancy in IPMN [16-21]. In a recent Japanese retrospec-
tive study [22], 17 clinical, radiological and pathological
parameters were considered in 64 patients operated on
in a 19 years period, defining a prognostic score in
which the dimensional cut-off was fixed in 42 mm for
the principal cyst and in 6.5 mm for the Wirsung duct,
while the CA19.9 discriminant value was 35 U/mls;
further parameters considered were jaundice, diabetes, a
pathological papilla and the principal duct involvement.
Nevertheless, 19/64 patients of this series had a total
score of 2 to 4, that didn’t allow to define them with
certainty as benign or malignant. Among all the ana-
lyzed factors, the distinction between MDT (Fig. 2) and
BDT (Fig. 3) is confirmed of maximum prognostic value
in almost all the series, the second presenting a malig-
nant potential of about 25% (ranging from 6% to 46%),
compared to 70% for the former (60-92%) [2]. Not all
main duct IPMNs are malignant at diagnosis; neverthe-
less, resection should be proposed in such cases, consid-
ering that: 1) survival of the patients resected for in situ
carcinoma is 100%, while it is 60% in presence of infil-
trative carcinoma; 2) up to now we cannot obtain by
preoperative means a definitive differentiation of dyspla-
sia from carcinoma; 3) the transition from a benign to a
malignant form is postulated. The most representative
series of main duct IPMN includes 140 patients, of
which 60% presented a malignant lesion and 41% nodal
metastases [5]. In our series, 10 patients have been sub-
mitted to pancreatic resection for main duct tumour:
7 had a carcinoma (2 in situ and 5 infiltrating), multifo-
cal in 3 cases and 1 patient had nodal metastases.
Results are encouraging in this subset of pancreas can-
cer: just the patient with nodal metastases died
16 months after the intervention, while the remaining
6 are all alive and disease free, with a follow up ranging
from 15 and 70 months (mean 42 months). Other
Figure 2 Colangio-MRI: main duct IPMN involving the whole
gland, three-dimensional and axial reconstruction.
Figure 3 Colangio-MRI: branch duct IPMN, clear documentation
of the communication with the Wirsung duct.
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studies also reported good outcomes for the resected
patients, being 5 year disease free survival rate about
90% for patient with non invasive cancer, 80% for inva-
sive cancers and 65% for patients with nodal metastases
[6,9,21]. Thus, with an almost certain diagnosis of intra-
ductal neoplasia involving the Wirsung, a demolitive
surgery appears to be justified.
An at least partial conservation of the gland to pre-
serve its exocrine and endocrine function should be part
of the strategy of the operation to guarantee a good
quality of life to patients who are expected to survive
for a long time, and often definitely recover. Neverthe-
less, the recurrent multifocal involvement of the Wir-
sung duct sets a limit to the respect of such principle.
In our series, we were obliged to extend the resection to
the whole gland in 6 out of 10 cases, while in 3 we pro-
ceeded to a distal resection and in 1 to an enlarged
proximal resection (subtotal duodeno-pancreatectomy).
The patients submitted to total pancreatectomy had
an obvious whole Wirsung disease from preoperative
imaging in 4 cases, while in the remaining 2 the intrao-
perative frozen sections examination imposed the exten-
sion of the pancreas demolition. A recent paper
reporting 127 partial pancreatectomies for IPMN shows
the difficulty to perform limited resections: in 29% of
the cases it was necessary to extend the resection, up to
a maximum of 4 re-resections, during the same opera-
tion, to obtain a negative margin [23]. In 8% of the this
series the Wirsung duct was de-epithelized at the mar-
gin and this alteration seems to represent a significant
prognostic factor for recurrence; this was reported also
previously [24]. In the same series the definitive diagno-
sis at the margin of the resection was different from the
intra-operative results in 6% of the cases. In 19% of 43
patients analyzed by Eguchi through a complex strategy
of separate cytology in the different lines of the gland
[25], the IPMN resulted to be discontinuous along the
Wirsung duct. Moreover the definition of positive sec-
tion margin is not established: for some Authors it con-
sists in the presence of intraductal papillomatosis even
in absence of displasia, for others the displasia of various
degree must be present [2].
The branch duct IPMNs (Fig. 3), on the other side,
have a better behaviour and prognosis, similar to cystic
mucinous neoplasm. In the Verona-Boston series of 145
resected patients, only 22% harboured a malignant can-
cer, all well characterized in their morphology by a cyst
greater than 3 cm, with a wall greater that 3 mm, and
nodules or papillae in the cyst [26]. The same Authors
reported 163 patient resected for cystic mucinous
tumor,17.5% of which were malignant, but never when
maximum size was lower than 4 cm and in absence of
nodules/papillae [27]. The 26 branch duct IPMNs
included in our paper, 3 resected and 23 observed, from
the first observation had been classified as benign and
they confirmed their benign nature at the histopathology
for the resected ones or, if not operated, showing no
change at a 28 months mean follow-up. This is in accord
with the results of a recent publications from an Ameri-
can multicentric [28] and a Japanese monocentric [29]
series; in both studies intraductal branch-duct tumours
followed without surgery, clearly showed that it is rarely
necessary to perform surgery for a dimensional evolution
or for the appearance of radiological elements of suspect
(11/70 and 7/82 patients respectively), and that the evo-
lution to carcinoma is rare eventuality (1 carcinoma in
situ in both series). Thus, carcinoma in an intraductal
branch duct tumour is to be suspected in presence of
jaundice and weight loss, or cyst greater than 30 mm or
intramural nodules. In patients who doesn’t present such
characteristics just an instrumental follow-up is
indicated.
Conclusions
The reported series of IPMNs from a Surgical Depart-
ment confirms the published guidelines: main duct
IPMNs have an high risk for malignancy and should be
operated on whenever possible, while for branch duct
IPMNs clinical and morphological parameters may
prove useful to choose the better treatment.
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